Pancreatic Fistula Risk Score (FRS) after Pancreatoduodenectomy
Validated risk score for clinically relevant postoperative pancreatic fistula (CR-POPF) after pancreatoduodenectomy (Whipple procedure). Based on gland texture, pathology, pancreatic duct diameter, and intraoperative blood loss. Score 0-10; score 7-10 = high risk. From Callery et al. 2013 and modified Fistula Risk Score (a-FRS) by Mungroop et al. 2019.
Score interpretation
FRS 0 -- negligible risk of clinically relevant POPF
→ Standard post-Whipple care; drain amylase monitoring on day 3 (if drain amylase below 3x serum: consider drain removal); regular vital signs and abdominal examination; drain output monitoring; resume oral diet when tolerated (day 2-3); early drain removal protocol if low amylase; standard surgical follow-up; no additional intervention required for fistula risk.
FRS 1-2 -- low risk of CR-POPF
→ Standard post-Whipple monitoring; day 3 drain amylase; if amylase below 3x upper normal: remove drain; octreotide not routinely indicated at this risk level; regular bloods (WCC, CRP, amylase, LFTs) every 1-2 days; early mobilisation and nutritional support; ensure adequate analgesia; monitor for delayed gastric emptying (most common complication at this risk level).
FRS 3-6 -- moderate CR-POPF risk; enhanced monitoring
→ Extended drain monitoring: daily drain amylase and output; if day 3 drain amylase above 3x normal: maintain drain -- assess for ISGPF Grade A/B/C fistula; prophylactic octreotide use per institutional protocol (controversial but often given in moderate/high risk); CT scan if signs of intra-abdominal collection (fever, rising CRP, abdominal pain); surgical or radiology-guided drain if collection develops; proton pump inhibitor to protect anastomosis; ensure hepatopancreatobiliary (HPB) consultant aware; MDT review if drain output persists beyond day 5.
FRS 7-10 -- high risk of CR-POPF; intensive monitoring required
→ HPB/pancreatic surgery consultant high-risk protocol; extended drain (maintain for minimum 5-7 days); daily drain amylase; octreotide 100-200 mcg TDS SC for 7 days (reduces pancreatic exocrine secretion); high clinical vigilance for sepsis and fistula signs; early CT if any concern (fever, rising WCC/CRP, abdominal symptoms); consider prophylactic external pancreatic drainage (surgeon decision intraoperatively); if Grade B/C fistula develops: interventional radiology review for drain placement, endoscopy for duct stenting, or surgical re-exploration; ICU monitoring first 48-72 hours; document plan and fistula risk score in operative note and handover.
Interpretation bands for the Pancreatic Fistula Risk. Apply clinical judgement and local guidance.
References
- Callery MP et al. A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreatoduodenectomy. J Am Coll Surg. 2013;216(1):1-14.
- Mungroop TH et al. Alternative Fistula Risk Score (a-FRS) for Pancreatoduodenectomy. Ann Surg. 2019;269(5):937-943.
Related
Curated clinical cross-links plus same-class fallbacks.
- Octreotide (Surgical — Fistula/Carcinoid) · Somatostatin Analogue
- Protamine Sulphate (Heparin Reversal) · Heparin Reversal / Cardiac Surgery
- Octreotide · Gastrointestinal Emergency
- Octreotide · Somatostatin Analogue
- Orlistat · Pancreatic lipase inhibitor
- Pancreatin (Pancreatic Enzyme Replacement Therapy — PERT) · Pancreatic Enzyme Supplement
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.